PMID: Summary Keywords Crohns disease, GLP, GLP-1, GLP-2 receptor agonist, IBD - inflammatory bowel disease, ulcerative colitis Citation Lee JJ, Bajgain P and Lightner AL (2026) GLP-1 and GLP-2 as intestinal reparative therapies in inflammatory bowel disease: mechanisms, translation, and clinical opportunity
Orrego-Gonzlez E, Peralta-Garca A, Palacios-Snchez L
Although pantethine therapy appears to be well tolerated, medical supervision is indispensable
Regarding fibrosis, while direct anti-fibrotic mechanisms are less established, preclinical studies indicate that GLP-1 RAs could suppress fibrogenic cell activation and reduce expression of pro-fibrotic genes encoding extracellular matrix proteins, potentially facilitating fibrosis regression in conjunction with improvements in steatosis and inflammation [29-32]
In addition, the second cycle of IRA drug-pricing negotiations resulted in agreements for a 71% discount for three well-known GPI-1s, Wegovy, Ozempic and Rybelsus that will take effect on January 1, 2027